

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FIFTEENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM DECEMBER 1, 2020 THROUGH DECEMBER 31, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	December 1, 2020 through December 31, 2020
Monthly Fees Incurred:	\$308,146.00

---

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$308,146.00

This is a: X monthly \_\_\_\_\_ interim \_\_\_\_\_ final application

**PRIOR APPLICATIONS:**

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$35,569.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$284,862.80	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$360,661.60	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, and \$10,000 were allocated evenly across fees from the first, second, and third interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from December 1, 2020 through and including December 31, 2020 (the “**Fee Period**”) amount to:

Professional Fees	\$308,146.00
Expenses	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$308,146.00</u></b>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$246,516.80
Expenses at 100%	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$246,516.80</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than March 31, 2021 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
March 17, 2021

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
Three Times Square, 10<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

EXHIBIT A

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649  
SUMMARY OF HOURS BY PROFESSIONAL  
FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020

Professional	Position	Specialty	Billing Rate <sup>1</sup>	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085	74.6	\$ 80,941.00
Joffe, Steven	Senior Managing Director	Tax	1,125	7.5	8,437.50
Simms, Steven	Senior Managing Director	Restructuring	1,295	2.7	3,496.50
Broadhead, Gary	Managing Director	International Healthcare	1,000	1.0	1,000.00
Blonder, Brian	Managing Director	Intellectual Property	750	22.3	16,725.00
Shah, Jayshree	Senior Director	International Healthcare	930	1.0	930.00
Suric, Emil	Senior Director	Healthcare	820	2.0	1,640.00
Bromberg, Brian	Director	Restructuring	815	156.8	127,792.00
Kim, Ye Darm	Senior Consultant	Restructuring	560	101.0	56,560.00
Kurtz, Emma	Consultant	Restructuring	415	25.6	10,624.00
<b>GRAND TOTAL</b>				<b>394.5</b>	<b>\$ 308,146.00</b>

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT B**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**

**SUMMARY OF HOURS BY TASK**

**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Code</b>	<b>Task Description</b>	<b>Total Hours</b>	<b>Total Fees</b>
1	Current Operating Results & Events	5.7	\$ 2,566.50
2	Cash & Liquidity Analysis	0.6	\$ 651.00
7	Analysis of Domestic Business Plan	78.3	\$ 60,411.00
10	Analysis of Tax Issues	19.9	\$ 18,837.50
13	Analysis of Other Miscellaneous Motions	0.5	\$ 542.50
16	Analysis, Negotiate and Form of POR & DS	165.9	\$ 129,807.00
18	Review of Historical Transactions	59.8	\$ 44,091.00
19	Case Management	7.7	\$ 4,754.00
21	General Meetings with Counsel and/or Ad Hoc Committee	15.0	\$ 14,700.00
22	Meetings with Other Parties	5.3	\$ 5,750.50
24	Preparation of Fee Application	6.6	\$ 5,391.00
28	Review of IAC Business Plan	29.2	\$ 20,644.00
<b>GRAND TOTAL<sup>1</sup></b>		<b>394.5</b>	<b>\$ 308,146.00</b>

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
1	12/1/2020	Diaz, Matthew	0.3	Review the updated Nalmafene Oct YTD spend.
1	12/1/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/2/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/3/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/4/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/7/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/8/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/9/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/10/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/11/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/14/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/15/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/16/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/21/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
<b>1 Total</b>			<b>5.7</b>	
2	12/1/2020	Diaz, Matthew	0.6	Review of the updated cash flow and holdings reports.
<b>2 Total</b>			<b>0.6</b>	
7	12/1/2020	Bromberg, Brian	0.7	Discuss domestic sale values with Houlihan team.
7	12/2/2020	Bromberg, Brian	1.5	Participate in weekly Committee call re: Sackler negotiations and sale alternatives.
7	12/4/2020	Bromberg, Brian	0.5	Prepare for call with counsel re: domestic entities diligence.
7	12/4/2020	Bromberg, Brian	0.6	Participate in call with counsel re: domestic entities diligence workplan.
7	12/8/2020	Diaz, Matthew	0.7	Review the updated business plan forecast reconciliation analysis.
7	12/8/2020	Bromberg, Brian	2.8	Review bridge analysis of the latest domestic business plan.
7	12/9/2020	Bromberg, Brian	2.0	Review Houlihan cash flow analysis on domestic plan.
7	12/9/2020	Bromberg, Brian	1.1	Review domestic business plan bridge analysis.
7	12/11/2020	Diaz, Matthew	0.5	Review the updated regulatory analysis.
7	12/11/2020	Diaz, Matthew	0.8	Review the reconciliation of the segment business plan projections.
7	12/13/2020	Diaz, Matthew	0.6	Review the updated segment cash flows of the business plan.
7	12/15/2020	Diaz, Matthew	0.6	Review the Oxy patent portfolio and related next steps.
7	12/15/2020	Kim, Ye Darm	0.7	Participate in call with FTI pharma operations expert re: LOE assumptions.
7	12/15/2020	Bromberg, Brian	1.5	Review cash flow public entity slides.
7	12/15/2020	Bromberg, Brian	0.5	Discuss OxyContin projections with internal team.
7	12/15/2020	Suric, Emil	0.5	Participate on call re: LOE assumptions on OxyContin.
7	12/16/2020	Diaz, Matthew	0.8	Participate in a call with the Debtor to discuss the updated business plan.
7	12/16/2020	Kim, Ye Darm	0.9	Participate in call re: takeaways from call with PJT on the 2021 business plan.
7	12/16/2020	Kim, Ye Darm	0.5	Participate in call with PJT re: 2021 domestic business plan.
7	12/16/2020	Kurtz, Emma	0.5	Participate on call with Debtors' advisors to discuss the domestic 2021 business plan.
7	12/16/2020	Bromberg, Brian	1.7	Participate in call with Committee re: plan B considerations.
7	12/16/2020	Bromberg, Brian	1.2	Participate in calls with Debtors re: 2021 budget overview.



**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
7	12/16/2020	Bromberg, Brian	2.3	Create bridge to latest business plan scenario cash flows.
7	12/18/2020	Diaz, Matthew	0.7	Review of the OxyContin patent calendar and related next steps coming out of the call with the Debtors.
7	12/18/2020	Diaz, Matthew	1.1	Participate in a call with the Debtors to discuss the OxyContin patent calendar.
7	12/18/2020	Diaz, Matthew	0.6	Participate in a call with Houlihan re the revised business plan.
7	12/18/2020	Bromberg, Brian	1.1	Participate in call with Debtors re: LOE assumptions.
7	12/18/2020	Bromberg, Brian	0.4	Prepare core business only cash flow scenario.
7	12/18/2020	Bromberg, Brian	0.9	Review OxyContin patent LOE assumptions.
7	12/18/2020	Suric, Emil	1.5	Discuss with management on OxyContin LOE assumptions.
7	12/21/2020	Diaz, Matthew	1.1	Participate in a call with Houlihan re: the updated Purdue business plan.
7	12/21/2020	Diaz, Matthew	3.1	Detail review of the updated Purdue business plan.
7	12/21/2020	Kim, Ye Darm	1.1	Participate in call with HL re: updated domestic business plan.
7	12/21/2020	Kim, Ye Darm	0.9	Process revisions to the December business plan bridging analysis.
7	12/21/2020	Kim, Ye Darm	0.7	Participate in call re: updated domestic business plan diligence.
7	12/21/2020	Kim, Ye Darm	2.2	Prepare analysis of Rhodes cash flow bridges re: updated December business plan.
7	12/21/2020	Kim, Ye Darm	2.8	Prepare bridging analysis to December business plan cash flows.
7	12/21/2020	Kurtz, Emma	1.1	Attend call with Houlihan to discuss the latest domestic business plan and updates to the analysis for the Committee.
7	12/21/2020	Kurtz, Emma	2.1	Prepare analysis of historical performance vs projected performance of Rhodes, Adhansia and Avrio segments to evaluate business plan projections.
7	12/21/2020	Kurtz, Emma	1.1	Prepare revisions to update slides for the Committee re: domestic business and distributable value per internal comments.
7	12/21/2020	Kurtz, Emma	1.1	Attend call with team to discuss revised domestic business plan and changes from prior business plan.
7	12/21/2020	Kurtz, Emma	0.8	Prepare updates to net distributable value slides for the Committee to incorporate revised business plan analysis.
7	12/21/2020	Bromberg, Brian	1.3	Discuss new domestic business plan with team.
7	12/21/2020	Bromberg, Brian	4.3	Review new domestic business plan model.
7	12/21/2020	Bromberg, Brian	1.0	Discuss new business plan with Houlihan team.
7	12/22/2020	Bromberg, Brian	2.5	Prepare bridges for updated business plan and scenarios.
7	12/22/2020	Bromberg, Brian	3.7	Update for new scenarios in presentation.
7	12/22/2020	Bromberg, Brian	2.6	Review new core only business scenario based on new business plan.
7	12/23/2020	Bromberg, Brian	1.8	Review updated bridge analysis from prior business plan.
7	12/23/2020	Bromberg, Brian	2.0	Participate in call with Debtors on public health initiatives.
7	12/23/2020	Bromberg, Brian	0.7	Finalize and send core only business scenario forecasts to Debtors for review.
7	12/28/2020	Kim, Ye Darm	2.6	Process revisions to slides re: upsides for Dec business plan.
7	12/28/2020	Kim, Ye Darm	0.7	Continue processing revisions to slides re: contingencies per Dec business plan.
7	12/28/2020	Kim, Ye Darm	0.4	Process revisions to contingencies slides re: Dec business plan.
7	12/28/2020	Kim, Ye Darm	0.6	Participate in discussion re: updated contingencies per Dec business plan.
7	12/28/2020	Bromberg, Brian	0.8	Discuss domestic plan updates with team.
7	12/28/2020	Bromberg, Brian	1.2	Discuss distributable value scenarios with team.
7	12/28/2020	Bromberg, Brian	1.3	Discuss scenarios presentation with Houlihan team.
7	12/29/2020	Bromberg, Brian	1.0	Review revised domestic business plan slides for presentation.
7	12/31/2020	Bromberg, Brian	1.9	Discuss business plan downside and upside scenarios.
<b>7 Total</b>			<b>78.3</b>	
10	12/1/2020	Joffe, Steven	1.5	Participate in call with IAC tax advisors.
10	12/1/2020	Bromberg, Brian	1.1	Participate in call with IAC tax advisors.
10	12/1/2020	Bromberg, Brian	0.7	Participate in pre call re: IAC tax.
10	12/2/2020	Diaz, Matthew	0.8	Review the updated IAC tax analysis.
10	12/3/2020	Joffe, Steven	0.8	Review and discuss transfer pricing presentation and tax impact.
10	12/3/2020	Diaz, Matthew	1.5	Review KPMG's updated IAC tax analysis.
10	12/3/2020	Diaz, Matthew	0.6	Review draft slide summarizing KPMG's tax analysis.
10	12/3/2020	Bromberg, Brian	1.0	Discuss transfer pricing tax issues with team.
10	12/3/2020	Bromberg, Brian	0.8	Process revisions to transfer pricing and tax impact slides.
10	12/3/2020	Bromberg, Brian	1.2	Prepare transfer pricing tax summary.
10	12/3/2020	Bromberg, Brian	1.0	Discuss transfer pricing tax summary with team.
10	12/3/2020	Bromberg, Brian	0.8	Continue to discuss transfer pricing tax issue with team.
10	12/4/2020	Joffe, Steven	0.8	Participate in discussion with counsel regarding tax analysis presentation.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
10	12/4/2020	Bromberg, Brian	0.6	Update tax impact summary slides for internal comments.
10	12/7/2020	Bromberg, Brian	0.5	Continue processing revisions to tax impact summary slides for internal comments.
10	12/8/2020	Bromberg, Brian	0.4	Discuss tax impact summary slides with Debtor and UCC advisors.
10	12/9/2020	Joffe, Steven	2.3	Review tax impact summary slides and discuss with AHC.
10	12/10/2020	Bromberg, Brian	0.4	Discuss tax impact summary slides with internal team.
10	12/10/2020	Bromberg, Brian	0.9	Create draft tax diligence question list for KPMG.
10	12/11/2020	Diaz, Matthew	0.6	Review the updated KPMG tax analysis.
10	12/15/2020	Bromberg, Brian	1.1	Continue drafting tax diligence questions for KPMG.
10	12/30/2020	Bromberg, Brian	0.5	Participate in call with Huron re: tax analysis.
<b>10 Total</b>			<b>19.9</b>	
13	12/2/2020	Diaz, Matthew	0.5	Review the exclusivity extension motion.
<b>13 Total</b>			<b>0.5</b>	
16	12/1/2020	Bromberg, Brian	0.8	Prepare for call re: sale values of domestic businesses.
16	12/1/2020	Bromberg, Brian	0.8	Participate in call re: sale values of domestic businesses.
16	12/1/2020	Diaz, Matthew	0.4	Review of the updated Debtors' segment valuations and related impact on the recovery analysis.
16	12/1/2020	Diaz, Matthew	1.0	Participate in a call with the Debtors' professionals to discuss the updated valuations by business segment.
16	12/2/2020	Bromberg, Brian	1.4	Discuss updated uses cash flow spreadsheet with internal team.
16	12/2/2020	Bromberg, Brian	0.5	Discuss updated uses cash flow spreadsheet with Houlihan team.
16	12/2/2020	Bromberg, Brian	1.5	Review Houlihan new analysis on cash flow.
16	12/2/2020	Diaz, Matthew	0.7	Review the updated slides on the distributable value analysis.
16	12/2/2020	Diaz, Matthew	1.7	Review the updated distributable value analysis.
16	12/2/2020	Kim, Ye Darm	0.8	Participate in discussion w/ HL re: Counsel's distributable value sensitivity scenarios.
16	12/2/2020	Kim, Ye Darm	3.5	Prepare distributable sensitivity scenarios suggested by Counsel.
16	12/2/2020	Kim, Ye Darm	0.9	Process revisions to slides re: Counsel's distributable value sensitivity scenarios.
16	12/2/2020	Kim, Ye Darm	1.8	Prepare slides re: counsel's proposed distributable value sensitivity scenarios.
16	12/2/2020	Kim, Ye Darm	0.9	Process revisions to the slides re: Counsel's distributable value scenarios.
16	12/2/2020	Simms, Steven	0.6	Review diligence workplan re: strategic alternatives.
16	12/3/2020	Bromberg, Brian	1.3	Discuss shut down costs with Houlihan.
16	12/3/2020	Bromberg, Brian	2.0	Participate in call re: DOJ and NCSG mediation positions.
16	12/3/2020	Diaz, Matthew	1.1	Review materials related to possible indication of interest.
16	12/3/2020	Diaz, Matthew	1.4	Review the updated distributable value recovery analysis.
16	12/3/2020	Kim, Ye Darm	1.8	Participate in meeting w/ DOJ re: go-forward considerations.
16	12/3/2020	Kim, Ye Darm	1.1	Prepare support slides for HL presentation re: strategic options.
16	12/4/2020	Bromberg, Brian	1.3	Review latest draft of domestic strategic alternatives presentation.
16	12/4/2020	Diaz, Matthew	0.8	Participate in a call with Counsel to discuss the go forward structure of Purdue.
16	12/4/2020	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the minimum cash assumptions used in the recovery analysis.
16	12/4/2020	Kim, Ye Darm	0.6	Participate in call w/ Counsel re: structuring considerations.
16	12/4/2020	Kim, Ye Darm	0.4	Review domestic business legal entity organizational structure.
16	12/5/2020	Bromberg, Brian	2.3	Review latest draft of sale alternatives presentation.
16	12/6/2020	Bromberg, Brian	1.5	Participate in call with counsel re: sale alternatives.
16	12/6/2020	Bromberg, Brian	1.5	Review sale alternatives presentation questions from Houlihan.
16	12/6/2020	Diaz, Matthew	0.5	Participate in a call with Houlihan to discuss the updated distributable value presentation.
16	12/6/2020	Diaz, Matthew	0.8	Review the distributable value amounts to the public entities.
16	12/6/2020	Diaz, Matthew	1.2	Review the updated distributable value presentation.
16	12/7/2020	Bromberg, Brian	1.8	Review Houlihan presentation on domestic strategic alternatives.
16	12/7/2020	Diaz, Matthew	1.9	Review the updated distributable value presentation
16	12/7/2020	Kim, Ye Darm	0.5	Update slides re: distributable value scenarios under current settlement assumptions.
16	12/7/2020	Kim, Ye Darm	1.8	Prepare presentation slides re: distributable value scenarios under current settlement terms.
16	12/7/2020	Kim, Ye Darm	2.8	Prepare analysis re: distributable value scenarios under current settlement terms.
16	12/7/2020	Simms, Steven	0.6	Correspond with team on latest settlement considerations.
16	12/8/2020	Bromberg, Brian	1.3	Discuss domestic strategic alternatives presentation with Houlihan.
16	12/8/2020	Bromberg, Brian	1.0	Discuss Houlihan domestic strategic alternatives presentation with internal team.
16	12/8/2020	Bromberg, Brian	0.8	Participate in call with Debtors re: domestic alternative scenarios.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
16	12/8/2020	Bromberg, Brian	1.8	Review latest draft of Houlihan presentation on domestic strategic alternatives.
16	12/8/2020	Diaz, Matthew	2.1	Review the updated Purdue distributable value deck.
16	12/8/2020	Diaz, Matthew	1.3	Participate in conference call with Houlihan to discuss the updated distributable value deck.
16	12/8/2020	Kim, Ye Darm	3.6	Prepare analysis re: segment level cash flow build ups.
16	12/8/2020	Kim, Ye Darm	0.8	Participate in call re: segment level cash flow build up.
16	12/8/2020	Kim, Ye Darm	1.0	Participate in call w/ Debtors re: cash flow bridge analysis.
16	12/8/2020	Kim, Ye Darm	1.0	Participate in call re: cash flow assumptions in HL's deck
16	12/8/2020	Kim, Ye Darm	1.5	Participate in call with HL re: cash flow risk and assumptions.
16	12/9/2020	Bromberg, Brian	2.0	Participate in Committee call re: domestic strategic scenarios.
16	12/9/2020	Bromberg, Brian	1.2	Discuss Houlihan strategic alternatives presentation with team.
16	12/9/2020	Bromberg, Brian	0.5	Discuss strategic alternatives domestic presentation with Houlihan.
16	12/9/2020	Diaz, Matthew	1.6	Review and reconcile the distributable value presentation to the underlying source documents.
16	12/9/2020	Diaz, Matthew	2.7	Review the updated distributable value presentation.
16	12/9/2020	Kim, Ye Darm	0.8	Participate in call re: core business cash flow build up.
16	12/9/2020	Kim, Ye Darm	0.6	Participate in internal call re: HL presentation cash flow assumptions.
16	12/9/2020	Kim, Ye Darm	0.6	Continue discussion re: HL presentation cash flow assumptions.
16	12/9/2020	Kim, Ye Darm	2.8	Prepare bottoms up analysis of core business cash flows.
16	12/9/2020	Kim, Ye Darm	1.6	Continue analysis re: build up of segment level cash flows to PBC case estimates.
16	12/10/2020	Kim, Ye Darm	1.4	Participate in call with DOJ and NCSG re: go-forward considerations.
16	12/10/2020	Kim, Ye Darm	2.2	Process revisions to core business cash flow build up analysis.
16	12/11/2020	Diaz, Matthew	0.8	Participate in a call with the UCC's advisors to discuss possible strategic alternatives.
16	12/11/2020	Kim, Ye Darm	1.0	Participate in discussion re: core business cash flow build up.
16	12/11/2020	Kim, Ye Darm	0.6	Update core business cash flow analysis.
16	12/11/2020	Kim, Ye Darm	1.0	Participate in call with UCC re: strategic alternatives.
16	12/14/2020	Diaz, Matthew	0.5	Review parameters of distribution analysis being requested from the Debtors.
16	12/14/2020	Diaz, Matthew	0.8	Review the updated distributable value analysis.
16	12/15/2020	Kim, Ye Darm	3.1	Prepare distributable value sensitivity case analysis for new scenarios.
16	12/15/2020	Kim, Ye Darm	1.8	Prepare draft presentation slides re: new distributable value scenarios.
16	12/16/2020	Diaz, Matthew	0.7	Review cash flow slides related to certain strategic alternative sensitivities.
16	12/16/2020	Kim, Ye Darm	0.7	Review Counsel's alternative plan structure presentation.
16	12/16/2020	Kim, Ye Darm	0.6	Process additional revisions to the distributable value sensitivity case slides.
16	12/16/2020	Kim, Ye Darm	1.2	Process revisions to distributable value sensitivity case scenario slides.
16	12/17/2020	Diaz, Matthew	2.1	Review the updated distributable value analysis.
16	12/21/2020	Bromberg, Brian	2.1	Edit draft slides for domestic scenarios presentation.
16	12/21/2020	Bromberg, Brian	2.2	Create comparison bridge analysis file for new cash flow adjustments.
16	12/21/2020	Bromberg, Brian	1.3	Review updated slides for domestic scenarios presentation.
16	12/21/2020	Bromberg, Brian	2.7	Process revisions to slides for domestic scenarios presentation.
16	12/21/2020	Bromberg, Brian	1.8	Update distribution analysis based on new plan forecasts.
16	12/21/2020	Diaz, Matthew	0.8	Review presentations on alternative plan constructs.
16	12/21/2020	Diaz, Matthew	1.2	Review the updated distributable value presentation.
16	12/21/2020	Kim, Ye Darm	3.2	Update distributable value scenario analyses for latest business plan forecasts.
16	12/22/2020	Bromberg, Brian	1.3	Review updated domestic business plan scenarios.
16	12/22/2020	Bromberg, Brian	2.0	Participate in call with DOJ and NCSG re: domestic business plan scenarios.
16	12/22/2020	Bromberg, Brian	1.9	Discuss updating all domestic strategic scenarios with Houlihan team.
16	12/22/2020	Diaz, Matthew	2.0	Participate in a call with the DOJ and key creditor groups on the updated distributable value analysis.
16	12/23/2020	Bromberg, Brian	1.9	Update slides for domestic strategic scenarios presentation.
16	12/23/2020	Bromberg, Brian	1.2	Discuss latest domestic strategic scenarios with team.
16	12/23/2020	Bromberg, Brian	2.6	Review the latest draft domestic strategic scenarios.
16	12/23/2020	Diaz, Matthew	1.6	Review the updated distributable value analysis.
16	12/24/2020	Bromberg, Brian	0.8	Respond to strategic scenarios diligence questions from Houlihan.
16	12/24/2020	Bromberg, Brian	2.4	Update slides for scenarios presentation based on new numbers.
16	12/28/2020	Bromberg, Brian	1.3	Review domestic strategic alternatives slides.
16	12/28/2020	Bromberg, Brian	1.8	Process revisions to strategic alternatives appendix slides.
16	12/28/2020	Bromberg, Brian	1.0	Review strategic alternatives appendix slides.
16	12/28/2020	Bromberg, Brian	1.2	Review PEO information in domestic strategic alternatives slides.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
16	12/28/2020	Bromberg, Brian	1.8	Update strategic alternatives appendix slides for new assumptions.
16	12/28/2020	Bromberg, Brian	0.9	Review new distributable value model.
16	12/28/2020	Diaz, Matthew	3.1	Review the updated distributable value analysis.
16	12/28/2020	Kim, Ye Darm	1.7	Process revisions to allocation model and slides for new contingencies.
16	12/28/2020	Kim, Ye Darm	0.5	Participate in discussion re: updated strategic considerations presentation.
16	12/28/2020	Kim, Ye Darm	2.1	Process updates to strategic alternatives distributable value slides for new contingencies.
16	12/29/2020	Bromberg, Brian	1.0	Discuss strategic scenarios presentation with Houlihan team and counsel.
16	12/29/2020	Kim, Ye Darm	1.6	Process updates to model and allocation slides for new contingencies for bid scenario.
16	12/29/2020	Kim, Ye Darm	0.7	Participate in discussion re: revisions to contingencies re: scenarios analysis.
16	12/29/2020	Kim, Ye Darm	0.9	Process additional revisions to slide and model per HL updated contingencies.
16	12/30/2020	Bromberg, Brian	2.2	Update team on UCC call re: scenario analysis.
16	12/30/2020	Bromberg, Brian	1.7	Review Houlihan distributable model on strategic scenarios.
16	12/30/2020	Bromberg, Brian	0.8	Review distribution slides for scenario presentation.
16	12/30/2020	Bromberg, Brian	0.8	Participate in call with Akin and Province re: strategic scenario analysis.
16	12/31/2020	Bromberg, Brian	2.0	Review net present values on strategic scenarios.
16	12/31/2020	Bromberg, Brian	1.1	Discuss updated OxyContin forecast with team.
16	12/31/2020	Bromberg, Brian	2.8	Edit distribution slides for presentation.
16	12/31/2020	Bromberg, Brian	1.2	Discuss strategic scenarios analysis with team.
16	12/31/2020	Bromberg, Brian	1.6	Discuss domestic business strategic scenarios presentation.
16	12/31/2020	Kim, Ye Darm	1.1	Prepare revisions to distributable value slides for updated downside contingency calculations.
16	12/31/2020	Kim, Ye Darm	0.7	Continue processing revisions to distributable value slides for updated downside contingencies.
16	12/31/2020	Kim, Ye Darm	0.8	Prepare updated allocation analysis per HL's updated contingency calculations.
16	12/31/2020	Kim, Ye Darm	0.6	Review latest downslide slide for strategic alternatives presentation.
<b>16 Total</b>			<b>165.9</b>	
18	12/1/2020	Blonder, Brian	2.3	Review Horst Frisch reports re: transfers analysis diligence.
18	12/1/2020	Kim, Ye Darm	2.6	Continue processing updates to draft transfers analysis presentation.
18	12/1/2020	Kim, Ye Darm	2.9	Process updates to draft transfers analysis presentation.
18	12/1/2020	Kim, Ye Darm	0.6	Participate in call re: transfers diligence analysis presentation.
18	12/1/2020	Kurtz, Emma	0.3	Discuss with team re: updates to analysis of historical transfers and comparison to other advisors damages conclusions.
18	12/1/2020	Bromberg, Brian	2.3	Review the non-cash transfers report.
18	12/1/2020	Bromberg, Brian	0.8	Review materials provided on royalty transfers.
18	12/1/2020	Bromberg, Brian	0.5	Discuss non-cash transfers diligence with team.
18	12/2/2020	Blonder, Brian	0.8	Gather materials regarding success probabilities for drug development projects.
18	12/2/2020	Blonder, Brian	1.9	Perform searches on ktMine in effort to find 8 Horst Frisch (HF) agreements or related materials re: transfers analysis.
18	12/2/2020	Kim, Ye Darm	1.1	Process revisions to transfers diligence analysis presentation.
18	12/2/2020	Bromberg, Brian	1.8	Process updates to non-cash transfers slides.
18	12/2/2020	Bromberg, Brian	2.6	Review and edit non-cash transfers report.
18	12/3/2020	Blonder, Brian	2.4	Begin review of information found in ktMine regarding 8 HF agreements.
18	12/4/2020	Blonder, Brian	2.7	Finish review of materials from ktMine regarding 8 HF agreements.
18	12/4/2020	Blonder, Brian	1.4	Create excel worksheet summary of information regarding 8 HF agreements.
18	12/4/2020	Bromberg, Brian	1.6	Review latest draft of non-cash transfers diligence report.
18	12/8/2020	Blonder, Brian	1.5	Participate in call with Bates White to discuss royalty analysis.
18	12/8/2020	Diaz, Matthew	1.5	Participate in call with Bates White to discuss royalty analysis.
18	12/8/2020	Kim, Ye Darm	1.5	Participate in call with Bates White to discuss royalty analysis.
18	12/8/2020	Kim, Ye Darm	1.0	Participate in call w/ Huron re: B-Side real estate support.
18	12/8/2020	Kurtz, Emma	1.5	Participate in call w/ Huron re: B-Side real estate support.
18	12/8/2020	Bromberg, Brian	0.7	Participate in call with Huron re: Side B transfers.
18	12/8/2020	Bromberg, Brian	0.7	Review royalty materials after call with Bates White.
18	12/8/2020	Bromberg, Brian	1.6	Participate in call w/ Huron re: B-Side real estate support.
18	12/9/2020	Blonder, Brian	0.5	Participate in call with restructuring team to discuss royalty analysis status.
18	12/9/2020	Blonder, Brian	1.7	Research drug formulations in 27 Bates White agreements for those covering pain medications.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
18	12/9/2020	Blonder, Brian	1.1	Create worksheet summarizing info on Bates White agreements covering pain medications.
18	12/9/2020	Diaz, Matthew	0.7	Review the updated royalty rate observations in connection with the non-cash transfer analysis.
18	12/9/2020	Kim, Ye Darm	0.5	Participate in discussion re: royalty analyses for transfers damages.
18	12/9/2020	Bromberg, Brian	0.6	Participate in discussion re: royalty analyses for transfers damages.
18	12/9/2020	Bromberg, Brian	0.6	Prepare for call re: royalties transfers damages.
18	12/11/2020	Diaz, Matthew	0.5	Review the updated side-b asset analysis.
18	12/15/2020	Kim, Ye Darm	0.6	Review latest draft of the collectability presentation on transfers.
18	12/16/2020	Kim, Ye Darm	1.1	Review latest draft of the transfer analysis presentation.
18	12/16/2020	Bromberg, Brian	2.5	Process revisions to transfer analysis diligence presentation.
18	12/17/2020	Blonder, Brian	3.0	Prepare slides for portion of presentation discussing royalty analysis work.
18	12/17/2020	Kim, Ye Darm	0.9	Review and process revisions to the transfers analysis presentation.
18	12/17/2020	Kurtz, Emma	0.3	Review presentation analyzing damages related to historical transfers to ensure correctness.
18	12/17/2020	Bromberg, Brian	0.8	Finalize draft transfer analysis presentation.
18	12/18/2020	Blonder, Brian	3.0	Prepare worksheets supporting the summary of conclusions regarding royalty analysis and creating slide presenting these results.
18	12/18/2020	Kim, Ye Darm	1.1	Review royalty analysis presentation slides and analysis.
18	12/22/2020	Diaz, Matthew	1.7	Review the updated transfers analysis.
<b>18 Total</b>			<b>59.8</b>	
19	12/7/2020	Kurtz, Emma	0.4	Review recently received diligence documents to update dataroom index and share with team.
19	12/9/2020	Bromberg, Brian	0.7	Prepare for internal call on ongoing diligence workplans.
19	12/9/2020	Bromberg, Brian	0.8	Participate in call re: ongoing diligence workplan.
19	12/9/2020	Simms, Steven	0.4	Correspond with team on latest settlement considerations.
19	12/9/2020	Kim, Ye Darm	0.6	Participate in discussion re: open workstreams and diligence.
19	12/9/2020	Kurtz, Emma	0.6	Participate in call with team to discuss ongoing workstreams and identify open items.
19	12/10/2020	Kurtz, Emma	0.9	Review recently received diligence documents to update dataroom index.
19	12/14/2020	Kurtz, Emma	0.4	Prepare updated dataroom index to reflect recently received diligence documents from the Company.
19	12/16/2020	Bromberg, Brian	0.9	Prepare for internal call re: ongoing diligence workstreams.
19	12/16/2020	Kurtz, Emma	0.5	Participate in call with team to discuss open items and upcoming deliverables, with a focus on the 2021 domestic and IAC business plans.
19	12/17/2020	Kim, Ye Darm	0.6	Participate in meeting re: outstanding workstreams.
19	12/21/2020	Kurtz, Emma	0.4	Review recently uploaded diligence documents to the dataroom to share updates with team.
19	12/28/2020	Kim, Ye Darm	0.5	Participate in discussion re: ongoing diligence workstreams.
<b>19 Total</b>			<b>7.7</b>	
21	12/2/2020	Joffe, Steven	0.5	Participate in call with AHC re: tax considerations.
21	12/2/2020	Diaz, Matthew	1.5	Participate in a call with the AHC to discuss the status of the mediation and other topics.
21	12/6/2020	Diaz, Matthew	1.9	Participate in a call with the AHC professionals to discuss the updated distributable value presentation.
21	12/9/2020	Diaz, Matthew	1.9	Participate in a call with the AHC to discuss the updated distributable value model and certain strategic alternatives.
21	12/9/2020	Diaz, Matthew	0.9	Prepare for the call with the AHC on distributable values and strategic alternatives.
21	12/9/2020	Kim, Ye Darm	1.6	Participate in AHC call re: strategic alternatives.
21	12/16/2020	Diaz, Matthew	2.0	Participate in a call with the AHC to discuss the updated distributable value analysis.
21	12/16/2020	Kim, Ye Darm	2.0	Participate in call with AHC re: strategic considerations.
21	12/22/2020	Joffe, Steven	1.6	Participate in AHC meeting re: domestic strategic options for potential tax considerations.
21	12/22/2020	Simms, Steven	1.1	Participate in call with AHC on outstanding plan issues.
<b>21 Total</b>			<b>15.0</b>	
22	12/3/2020	Diaz, Matthew	1.6	Participate in a call with the AHC, NCSG and the DOJ to discuss plan emergence structures.
22	12/8/2020	Diaz, Matthew	0.3	Participate in a call with Province to discuss certain strategic alternatives.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
22	12/10/2020	Diaz, Matthew	1.4	Participate in a call with the NCSG, AHC and DOJ to discuss possible plan alternatives.
22	12/23/2020	Diaz, Matthew	2.0	Participate in a call with the DOJ, key creditor groups and the AHC to discuss the distributable value analysis.
<b>22 Total</b>			<b>5.3</b>	
24	12/1/2020	Diaz, Matthew	0.9	Review of the October fee app.
24	12/1/2020	Kim, Ye Darm	1.1	Process updates to October fee app.
24	12/14/2020	Kim, Ye Darm	0.7	Process revisions to FTI October bill.
24	12/15/2020	Diaz, Matthew	0.3	Review of the proposed interim fee order.
24	12/15/2020	Bromberg, Brian	1.5	Participate in omnibus hearing as FTI representative.
24	12/21/2020	Diaz, Matthew	1.3	Review the Purdue Nov fee app.
24	12/28/2020	Kim, Ye Darm	0.8	Process revisions to Nov fee app.
<b>24 Total</b>			<b>6.6</b>	
28	12/4/2020	Diaz, Matthew	0.3	Participate in a call with Alix to discuss the IAC tax issues.
28	12/4/2020	Diaz, Matthew	0.2	Participate in a call with the UCC to discuss the IAC tax implications.
28	12/7/2020	Diaz, Matthew	0.7	Review the updated IAC business plan analysis.
28	12/9/2020	Kurtz, Emma	0.8	Review analysis of September business plan in preparation for receipt of 2021 business plan.
28	12/9/2020	Bromberg, Brian	0.5	Discuss workplan for IAC business plan diligence.
28	12/10/2020	Diaz, Matthew	0.7	Review the latest IAC tax analysis.
28	12/10/2020	Diaz, Matthew	0.6	Draft and review correspondence to/from the UCC's financial advisor re tax analysis sensitivities.
28	12/14/2020	Kim, Ye Darm	0.9	Review variance analysis re: updated IAC business plan.
28	12/14/2020	Kim, Ye Darm	0.7	Review updated IAC business plan summary P&L.
28	12/14/2020	Kurtz, Emma	1.4	Analyze variance of IACs 2021 business plan to September 2020 business plan to prepare for call with management.
28	12/14/2020	Bromberg, Brian	1.0	Review updated IAC business plan and comparison analysis.
28	12/15/2020	Broadhead, Gary	1.0	Review latest diligence files uploaded re: IAC diligence.
28	12/15/2020	Diaz, Matthew	0.8	Review the historical IAC budgets to prepare for the call with the CEO and CFO on the revised budget.
28	12/15/2020	Diaz, Matthew	1.1	Participate in a call with the IAC management team to discuss YTD results and the revised budget.
28	12/15/2020	Kim, Ye Darm	1.0	Participate in call with IAC CEO re: YTD performance and 2021 business plan.
28	12/15/2020	Kurtz, Emma	1.0	Participate in call with IACs management and advisors to discuss the October YTD results and the 2021 business plan.
28	12/15/2020	Bromberg, Brian	1.0	Review IAC materials provided in dataroom.
28	12/15/2020	Bromberg, Brian	1.1	Participate in call with CEO and CFO of Mundipharma.
28	12/15/2020	Shah, Jayshree	1.0	Participate in call with IACs management and advisors to discuss the October YTD results and the 2021 business plan.
28	12/16/2020	Diaz, Matthew	0.4	Draft correspondence to Counsel re: the IAC budget and YTD results call.
28	12/16/2020	Diaz, Matthew	0.6	Review and supplement IAC tax due diligence questions to KPMG.
28	12/16/2020	Bromberg, Brian	0.8	Review IAC slides to create presentation outline.
28	12/17/2020	Kim, Ye Darm	1.3	Review BoD presentation to financial advisors re: IAC diligence.
28	12/17/2020	Kim, Ye Darm	0.7	Review draft deck of IAC 2021 business plan update.
28	12/17/2020	Kim, Ye Darm	0.6	Review IAC finance update presentation re: YTD performance.
28	12/17/2020	Kurtz, Emma	1.7	Prepare analysis of 2021 business plan to bridge 2020 to 2025 projections and evaluate growth drivers.
28	12/17/2020	Kurtz, Emma	0.3	Prepare revisions to IAC financial update presentation for the Committee re: internal comments.
28	12/17/2020	Kurtz, Emma	1.3	Prepare analysis re: October YTD IAC results to compare to budget.
28	12/17/2020	Kurtz, Emma	1.4	Prepare presentation for Committee re: IAC financial update, including October YTD results and 2021 business plan.
28	12/17/2020	Bromberg, Brian	1.5	Review draft IAC slides on latest business plan and YTD results.
28	12/21/2020	Kurtz, Emma	0.3	Prepare revisions to IAC update slides re: October YTD performance and 2021 business plan per internal comments.
28	12/21/2020	Bromberg, Brian	0.7	Finalize and distribute slides on IAC business plan and YTD results.
28	12/30/2020	Kim, Ye Darm	0.6	Clean up call notes for distribution to internal team re: IAC sale process update call.
28	12/30/2020	Kim, Ye Darm	0.6	Participate in call re: IAC sale process updates w/ DB.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD DECEMBER 1, 2020 TO DECEMBER 31, 2020

Task Category	Date	Professional	Hours	Activity
28	12/30/2020	Bromberg, Brian	0.6	Participate in call re: IAC sale process.
28 Total			29.2	
Grand Total			394.5	